The STING inhibitor C‐176 attenuates osteoclast‐related osteolytic diseases by inhibiting osteoclast differentiation
The FASEB Journal · 2023
DOI: 10.1096/fj.202201600r ↗Kurz gefasst
Fachartikel in der Zeitschrift The FASEB Journal, 2023. Verfasst von Zhen-Cheng Yu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Bone Resorption, Osteolysis, Arthritis. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Shanghai.
Abstract (Originalsprache)
Inflammatory osteolysis occurs primarily in the context of osteoarthritis, aseptic inflammation, prosthesis loosening, and other conditions. An excessive immune inflammatory response causes excessive activation of osteoclasts, leading to bone loss and bone destruction. The signaling protein stimulator of interferon gene (STING) can regulate the immune response of osteoclasts. C‐176 is a furan derivative that can inhibit activation of the STING pathway and exert anti‐inflammatory effects. The effect of C‐176 on osteoclast differentiation is not yet clear. In this study, we found that C‐176 could inhibit STING activation in osteoclast precursor cells and inhibit osteoclast activation induced by nuclear factor κB ligand receptor activator in a dose‐dependent manner. After treatment with C‐176, the expression of the osteoclast differentiation marker genes nuclear factor of activated T‐cells c1(NFATc1), cathepsin K, calcitonin receptor, and V‐ATPase a3 decreased. In addition, C‐176 reduced actin loop formation and bone resorption capacity. The WB results showed that C‐176 downregulated the expression of the osteoclast marker protein NFATc1 and inhibited activation of the STING‐mediated NF‐κB pathway. We also found that C‐176 could inhibit the phosphorylation of mitogen‐activated protein kinase signaling pathway factors induced by RANKL. Moreover, we verified that C‐176 could reduce LPS‐induced bone absorption in mice, reduce joint destruction in knee arthritis induced by meniscal instability, and protect against cartilage matrix loss in ankle arthritis induced by collagen immunity. In summary, our findings demonstrated that C‐176 could inhibit the formation and activation of osteoclasts and could be used as a potential therapeutic agent for inflammatory osteolytic diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Plastic and Reconstructive Surgery, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Burns & Plastic Surgery, Xiangya Hospital, Central South University, Changsha, China.
ORCID-Profile: Dong Han
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Shanghai
Zitieren
APA
Yu, Z. C., Fu, R., Li, Y., Zhao, D. Y., Jiang, H., & Han, D. (2023). The STING inhibitor C‐176 attenuates osteoclast‐related osteolytic diseases by inhibiting osteoclast differentiation. The FASEB Journal. https://doi.org/10.1096/fj.202201600r
Vancouver
Yu ZC, Fu R, Li Y, Zhao DY, Jiang H, Han D. The STING inhibitor C‐176 attenuates osteoclast‐related osteolytic diseases by inhibiting osteoclast differentiation. The FASEB Journal. 2023. doi:10.1096/fj.202201600r
BibTeX
@article{Yu2023,
author = {Yu, Zhen-Cheng and Fu, Rao and Li, Yun and Zhao, Dan-Yang and Jiang, Hao and Han, Dong},
title = {The STING inhibitor C‐176 attenuates osteoclast‐related osteolytic diseases by inhibiting osteoclast differentiation},
journal = {The FASEB Journal},
year = {2023},
doi = {10.1096/fj.202201600r}
}
EUVIMED